INO: Inovio Pharmaceuticals Growth-Adjusted Market Cap to Net Income

Inovio Pharmaceuticals develops DNA vaccines using the CELLECTRA system for targeted drug delivery, which, upon successful testing, guarantees a monopoly with low synthesis costs. The undervalued growth company search indicator reflects the dynamics of this potential, where 0.00 serves as the base parameter value. The asset's stability is supported by the neutral geopolitical status of humanitarian developments.

INO: Inovio Price/Earnings to Growth Multiple 07/04/2022 - 11/12/2026

Analytical breakdowns for Inovio Pharmaceuticals (INO)

- current price and projected stock value:

Price Chart Inovio Pharmaceuticals, Inc.|INO - Analyst Consensus Forecast

- market capitalization information:

Market Capitalization Inovio Pharmaceuticals Inc|INO - Total Company Value

- company book value details:

Accounting Value of a Share Inovio|INO - Company Net Assets|Market Capitalization to Book Value Ratio inovio.com|INO - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

- earnings and valuation multiples information:

INO - Net Profit|Company Profit Forecast Inovio Pharmaceuticals|INO - Price to Earnings Ratio|Projected Price to Earnings Ratio Inovio Pharma|INO - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Inovio Pharmaceuticals Inc|INO - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Inovio|INO - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months inovio.com|INO - Earnings growth in current year|Earnings growth forecast for next year Inovio Pharmaceuticals

Fundamental company analysis:Inovio Pharmaceuticals, Inc. (INO)

Fundamental selection of promising assets is based on identifying undervalued earnings expansion rates relative to market value. This indicator compares the P/E multiple with expected income growth, which, in the context of the unique DNA vaccine platform of Inovio Pharmaceuticals (INO), allows for an assessment of the discounting of a future drug market monopoly through the company's current PEG valuation.

Competitors of Inovio Pharmaceuticals